Gulf War Syndrome Clinical Trial
Official title:
Mechanisms of Mitochondrial Defects in Gulf War Syndrome
Verified date | April 2015 |
Source | Medical Neurogenetics, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Observational |
The purpose of the study is to investigate possible causes for Gulf War Syndrome. Gulf War Syndrome is associated with increased incidences of amyotrophic lateral sclerosis (Lou Gehrig's Disease), pain syndromes, muscle complaints that include fatigue and myalgias (muscle pain), as well as other neurological symptoms. Abnormalities in the part of the cell known as mitochondria have been delineated in Gulf War Syndrome. Mitochondria are the "power plants" of the body. Mitochondria take the food you eat and break the food down into a form of energy that the body can use. The investigators propose that Gulf War Syndrome is determined by a complex interaction of factors that interfere with mitochondrial function. This study will be the first investigation of mitochondrial function in Gulf War Syndrome. The investigators objective is to establish the cause for symptoms in affected veterans, develop testing that can more easily identify Gulf War Syndrome, and ultimately develop treatment protocols for Gulf War Syndrome.
Status | Completed |
Enrollment | 26 |
Est. completion date | June 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Short-term memory loss or a severe inability to concentrate that affects work, school or other normal activities - Muscle Pain, myalgias - Pain without redness or swelling in a number of joints - Intense or changing patterns of headaches - Unrefreshing sleep - After any exertion, weariness that lasts for more than a day Exclusion Criteria: - Organ failure (e.g. emphysema, cirrhosis, cardiac failure, chronic renal failure) - Chronic infections (e.g. HIV/AIDS, hepatitis B or C) - Rheumatic and chronic inflammatory diseases (e.g. systemic lupus erythematosis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease, chronic pancreatitis.) - Major neurologic diseases (e.g. multiple sclerosis, neuromuscular diseases, epilepsy or other disease requiring ongoing medication that could cause fatigue, stroke, head injury with residual neurologic deficits) - Diseases requiring systemic treatment (e.g. organ or bone marrow transplantation; systemic chemotherapy; radiation of brain, thorax, abdomen, or pelvis) - Major endocrine diseases (e.g. hypopituitarism, adrenal insufficiency) - Myocardial infarction, heart failure - Morbid obesity (body mass index >40) - Permanent psychiatric exclusions: Lifetime diagnoses of bipolar affective disorders, schizophrenia or any subtype, delusional disorders of any subtype, dementias of any subtype, organic brain disorders, and alcohol or substance abuse within 2 years before onset of the fatiguing illness. - History of allergic reaction to lidocaine - History of keloid formation with skin incisions. |
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
United States | Medical Neurogenetics, LLC | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Medical Neurogenetics, LLC | United States Department of Defense |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Characterize mitochondrial cellular energetics in Gulf War Syndrome patients | After collecting a skin and blood sample, mitochondrial cellular energetics in Gulf War Syndrome patients will be characterized by: 1. high resolution respirometry of intact cells, 2. quantitative analysis of individual mitochondrial proteins, 3. analysis of intact OXPHOS enzyme complexes and supercomplexes, 4. in gel enzyme activity assessment of intact OXPHOS enzyme complexes and supercomplexes, 5. mitochondrial DNA (mtDNA) copy number quantitation to assess for defects in regulation mtDNA replication and 6. cellular coenzyme Q10 quantitation. | approximately 2 years; once all data has been collected from study participants | No |
Secondary | Mitochondrial DNA | Assess the mitochondrial DNA (mtDNA) from each patient with Gulf War Syndrome for mtDNA mutations by whole genome sequencing of leukocyte and skin cell mtDNA. | approximately 2 years; once all data has been collected from study participants. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00129454 -
Telemedicine Treatment for Veterans With Gulf War Illness
|
N/A | |
Completed |
NCT00100412 -
Hyporeactivity and Gulf War Illness
|
N/A | |
Recruiting |
NCT04182659 -
Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
|
N/A | |
Recruiting |
NCT04987775 -
GWICTIC: NAC Mechanistic Study in Gulf War Veterans
|
Early Phase 1 | |
Completed |
NCT03342482 -
Glutamate Neuro-Excitotoxicity in GWI
|
N/A | |
Terminated |
NCT03547869 -
Transcranial Direct Current Stimulation for Pain Treatment in Gulf War Illness.
|
N/A | |
Recruiting |
NCT05675878 -
Confirmation of Diet as a Treatment for Gulf War Illness
|
Phase 3 | |
Recruiting |
NCT05736146 -
Validating Gulf War Illness Blood Biomarkers
|
||
Completed |
NCT03560830 -
START & STOPP in GWI
|
||
Recruiting |
NCT05355272 -
Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)
|
Phase 2 | |
Terminated |
NCT04712071 -
Ketamine in Veterans With Gulf War Illness
|
Early Phase 1 | |
Completed |
NCT03030794 -
Alleviating Headache and Pain in GWI With Neuronavigation Guided rTMS
|
N/A | |
Completed |
NCT04638998 -
Assessing Neuroinflammation in GWI Using MRS
|
||
Completed |
NCT02804828 -
Mitochondrial Cocktail for Gulf War Illness
|
N/A | |
Recruiting |
NCT02848417 -
Glutathione vs. Curcumin Clinical Trial
|
Phase 1/Phase 2 | |
Recruiting |
NCT00956150 -
Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex
|
Phase 1 | |
Completed |
NCT00018707 -
Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress
|
N/A | |
Not yet recruiting |
NCT05992311 -
Clinical Evaluation of Montelukast in Veterans With Gulf War Illness
|
Phase 1 |